Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Promyelocytic, Acute 3 Thrombocytopenia 2 Pathologic Complete Response 2 Uterine Cervical Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Multiple Myeloma 1 Lung Neoplasms 1 Leukemia 1 Laryngeal Neoplasms 1 Hypopharyngeal Neoplasms 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Digestive System Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Dexamethasone 114 daratumumab 68 Lenalidomide 66 Bortezomib 55 pomalidomide 44 carfilzomib 39 Cyclophosphamide 33 Specimen Handling 30 Calcium Dobesilate 30 Biopsy 27 Magnetic Resonance Spectroscopy 24 belantamab mafodotin 20 isatuximab 19 fludarabine 17 talquetamab 16 iberdomide 15 Melphalan 15 dexamethasone acetate 13 dexamethasone 21-phosphate 13 auricularum 13 fludarabine phosphate 11 selinexor 10 elotuzumab 10 tocilizumab 9 X-Rays 8 Nivolumab 8 Sirolimus 7 trametinib 6 Whole-Body Irradiation 6 Mycophenolic Acid 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × Tretinoin × 90 days × Clear all

NCT06536413 2026-04-03

ATRA

The Methodist Hospital Research Institute

Phase 1/2 Recruiting

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡